Merck Sharp & Dohme Corp.
144 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 29 name spellings.
Previously recorded as Trius Therapeutics, Inc. (to 2016)
484
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 4 fees due Nov 14 to 19, 2026 · next Nov 14
- 8 fees due Dec 2 to 30, 2026 · next Dec 2
- 24 fees due Jan 2 to 28, 2027 · next Jan 2
- 19 fees due Feb 4 to 28, 2027 · next Feb 4
- 30 fees due Mar 1 to 29, 2027 · next Mar 1
- 26 fees due Apr 1 to 30, 2027 · next Apr 1
- 22 fees due May 3 to 28, 2027 · next May 3
- 28 fees due Jun 1 to 30, 2027 · next Jun 1
- 35 fees due Jul 5 to 30, 2027 · next Jul 5
- 19 fees due Aug 4 to 25, 2027 · next Aug 4
- 28 fees due Sep 1 to 30, 2027 · next Sep 1
- 20 fees due Oct 5 to 30, 2027 · next Oct 5
- 13 fees due Nov 3 to 12, 2027 · next Nov 3
Recent changes
- 21 of the patents on this record were granted since Aug 16, 2026
- 47 terms have ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,816,380 | 1-Hydroxycycloalkanecarboxamide Derivatives In force · High confidence | In force | High confidence | |
| US 7,569,592 | Heteroaryl Substituted Pyrazole Modulators of Metabotropic Glutamate RECEPTOR-5 In force · High confidence | In force | High confidence | |
| US 7,625,938 | Substituted Pyrazoles, Compositions Containing Such Compounds and Methods of Use In force · High confidence | In force | High confidence | |
| US 8,486,983 | Self-Emulsifying Formulations of Cetp Inhibitors In force · High confidence | In force | High confidence | |
| US 7,528,132 | Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 8,298,543 | Identification and Application of Antibiotic Synergy In force · High confidence | In force | High confidence | |
| US 7,888,369 | Oxazoloisoquinoline Derivatives as Thrombin Receptor Antagonists In force · High confidence | In force | High confidence | |
| US 7,547,720 | Ophthalmic Compositions for Treating Ocular Hypertension In force · High confidence | In force | High confidence | |
| US 7,709,658 | Process for Synthesizing a Substituted Pyrazole In force · High confidence | In force | High confidence | |
| US 7,834,026 | Spirocyclic Compounds In force · High confidence | In force | High confidence |
Also on record, not counted in the 1,742: 144 patents in force now held by others · 1,261 lapsed for an unpaid fee · 1,402 ended at full term · 7 past the fee grace period · 4 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
226 pending · 496 abandoned · 26 no status recorded